Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (the "Shares")

Q: What does CUSIP 880881107 represent in this 13F holders report?

CUSIP 880881107 is the security identifier for 880881107 - Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (the "Shares") used to aggregate holder disclosures.

Q: How many institutions held 880881107 - Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (the "Shares") in Q2 2024?

2 institutional investors reported 880881107 - Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (the "Shares") for Q2 2024. Use the holders table for investor-level position and value details.

CUSIP: 880881107

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class: Equity / Common Stock, $0.0001 par value per share (the "Shares")
Shares outstanding: 84,519,683
Total 13F shares: 5,297,341
Share change: +1,076,318
Total reported value: $36,074,893
Price per share: $6.81
Number of holders: 2
Value change: +$7,329,726
Number of buys: 2

Quarterly Holders Quick Answers

What is CUSIP 880881107?
CUSIP 880881107 identifies 880881107 - Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (the "Shares") in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2024
Previous quarter: Q1 2024

Recent filing periods for CUSIP 880881107:

Q1 2026 Q4 2025 Q3 2024 Q2 2024 Q1 2024 Q4 2023

Top shareholders of 880881107 - Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (the "Shares") (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BlackRock Finance, Inc.	13F	Company	3.9%	3,315,529	$21,749,871	—	31 Mar 2024	13F
CITADEL ADVISORS LLC	13F	Company	3.5%	2,965,586	$19,454,245	—	31 Mar 2024	13F
STATE STREET CORP	13F	Company	1.1%	905,494	$5,940,041	—	31 Mar 2024	13F

Institutional Holders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (the "Shares") as of Q2 2024

As of 30 Jun 2024, Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (the "Shares") was held by 2 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 5,297,341 shares. The largest 4 holders included BlackRock Inc., CITADEL ADVISORS LLC, STATE STREET CORP, and RENAISSANCE TECHNOLOGIES LLC. This page lists 4 institutional shareholders reporting positions in this security for the Q2 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders

Q2 2024 holders

Holder diff

Investor	Q1 2024 Shares	Q2 2024 Shares	Share Diff	Share Chg %	Q1 2024 Value $	Q2 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.